HIT vs UNH

For growth investors, Health In Tech, Inc.

(HIT) is the stronger pick with 71. 0% revenue growth year-over-year, versus 11. 8% for UnitedHealth Group Incorporated (UNH). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 9x trailing P/E (20. 2x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.

9x versus Health In Tech, Inc. at 78. 5x.

Over the past 5 years, UnitedHealth Group Incorporated (UNH) delivered a total return of -2.

6%, compared to -69. 2% for Health In Tech, Inc. (HIT). Over 10 years, the gap is even starker: UNH returned +220. 6% versus HIT's -69. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), UnitedHealth Group Incorporated (UNH) is the lower-risk stock at 0.

59β versus Health In Tech, Inc. 's 2. 00β — meaning HIT is approximately 240% more volatile than UNH relative to the S&P 500. On balance sheet safety, Health In Tech, Inc. (HIT) carries a lower debt/equity ratio of 1% versus 77% for UnitedHealth Group Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health In Tech, Inc.

(HIT) is pulling ahead at 71. 0% versus 11. 8% for UnitedHealth Group Incorporated (UNH). On earnings-per-share growth, the picture is similar: Health In Tech, Inc. grew EPS 62. 6% year-over-year, compared to -14. 7% for UnitedHealth Group Incorporated. Over a 3-year CAGR, HIT leads at 79. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Health In Tech, Inc.

(HIT) is the more profitable company, earning 3. 8% net margin versus 2. 7% for UnitedHealth Group Incorporated — meaning it keeps 3. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIT leads at 4. 6% versus 4. 2% for UNH. At the gross margin level — before operating expenses — HIT leads at 62. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, UNH (2.

4% yield) pays a dividend. HIT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

59), 2. 4% yield, +220. 6% 10Y return). Health In Tech, Inc. (HIT) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UNH: +220. 6%, HIT: -69. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HIT (Technology) and UNH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HIT is a small-cap high-growth stock; UNH is a large-cap quality compounder stock. UNH pays a dividend while HIT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.